Global Indomethacin Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Suppositories, Injections, Capsules, Suspension, and Others), By Indications (Osteoarthritis, Gout, Ankylosing Spondylitis, Rheumatoid Arthritis, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023-2033

Global Indomethacin Market Insights Forecasts to 2033 and COVID-19 Impact Analysis.

• The Global Indomethacin Market Size Was Estimated at USD 1.08 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 6.41% from 2023 to 2033
• The Worldwide Indomethacin Market Size is Expected to reach USD 2.01 Billion By 2033
• Asia Pacific is Predicted to Grow at the Fastest CAGR throughout the Projection Period

The Global Indomethacin Market Size is Predicted to Exceed USD 2.01 Billion by 2033, Growing at a CAGR of 6.41% from 2023 to 2033.

Market Overview

The global indomethacin market involves the development, production, and commercialization of the indomethacin and its medications that are used in the management of pain, inflammation conditions like gout, arthritis, and ankylosing spondylitis. Indomethacin is referred to as indocin, indomethacin, and indocid. Indomethacin is a class of potent non-steroidal anti-inflammatory drugs (NSAIDs) used to treat mild to moderate acute pain and relieve symptoms of arthritis or gout. It inhibits prostaglandin synthesis, which is crucial for inflammation, fever, and pain. Indomethacin is FDA-approved; it is used to manage acute pain, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, gouty arthritis, and patent ductus arteriosus. However, DMARDs have shown superior efficacy in inhibiting rheumatoid arthritis progression, making Indomethacin a viable option for managing these conditions. The marketed products of the indomethacin are INDICID-75 SR tablets, Indowell 25 capsules, INDOMETACIN DS 25, etc.

The increasing prevalence of inflammatory diseases and conditions escalates the need for nonsteroidal anti-inflammatory medications such as indomethacin for the treatment of osteoarthritis, rheumatoid arthritis and to reduce inflammation, swelling, and pain, which results in the expansion of the indomethacin market. For instance, rheumatoid arthritis (RA) is a chronic disease causing inflammation and joint pain, affecting 18 million people globally in 2019. 70% of those with RA are women, and 55% are over 55. Rehabilitation is beneficial for 13 million people with moderate or severe severity. RA affects multiple body systems, with the joints of hands, wrists, feet, ankles, knees, shoulders, and elbows being most affected.

Various government initiatives drive the indomethacin market growth. For example, the Ministry of Health and Welfare launched the National Programme for Health Care of the Elderly (NPHCE) is addressing arthritis among the elderly by offering free or subsidised treatment in government hospitals. Affordable Medicines and Reliable Implants for Treatment (AMRIT) Deendayal outlets have been opened at over 200 institutions/hospitals to provide discounted drugs and implants. Jan Aushadhi stores provide generic drugs at affordable prices. The Pradhan Mantri Jan Arogya Yojna (PMJAY) provides cashless access to services in empanelled hospitals across India. The government plans to include arthritis in the National Health Programme.

Report Coverage

This research report categorizes the global indomethacin market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global indomethacin market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global indomethacin market.

Driving Factors:

Rising prevalence of rheumatoid arthritis:

Rheumatoid arthritis (RA) is a long-lasting disease that leads to joint inflammation and pain. It is affected by variables such as smoking, obesity, and environmental toxins, especially in urban and industrial regions. The impact on women is greater than that on men. The prevalence of RA rises with age, especially in the 40-to-70-year range. As the population ages, the demand for indomethacin, a drug used to treat RA, is increasing, as older individuals are more prone to RA and other inflammatory conditions. For instance, rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and symmetrical involvement of peripheral joints. It is prevalent worldwide, with prevalence ranging from 0.24% to 2%. RA affects both men and women, with an increased incidence above 40 years, with women 2 to 3 times more affected than men, with onset occurring at 60-70 years.

Innovations in the formulations and drug delivery methods:

The effectiveness and convenience of indomethacin are being enhanced by recent drug formulations and delivery systems. This encompasses sustained-release and extended-release formulations, which maintain consistent drug levels in the bloodstream over time and decrease the frequency of administration. New delivery methods, like topical creams, gels, and patches, aim to address localized inflammation while reducing systemic side effects, including gastrointestinal distress. These enhancements boost patient satisfaction and propel market growth. Indomethacin sustained-release tablets have been developed with components such as ethyl cellulose and HPMC K-100, which guarantee lasting therapeutic effects and a decrease in the frequency of administration. While liposomal formulations improve bioavailability and minimize gastrointestinal side effects, bilayer floating tablets consist of layers for both immediate and sustained release.

Restraining Factors

The stringent regulatory requirement, availability of alternative medications for the management of the inflammatory conditions, higher cost of the branded medications of the indomethacin, side effects derived from the prolonged use of such medications, and limited awareness in the middle income countries restrict the growth of the market.

Market Segmentation

The global indomethacin market share is classified into dosage form, indications, and distribution channel.

• The capsules segment accounted for a significant share in 2023 and is anticipated to grow at a remarkable CAGR throughout the forecast period.

Based on the dosage form, the global indomethacin market is categorized into suppositories, injections, capsules, suspension, and others.  Among these, the capsules segment accounted for a significant share in 2023 and is anticipated to grow at a remarkable CAGR throughout the forecast period. The segmental expansion is attributed to patient compliance, ease of administration, enhanced bioavailability, and availability of the novel drug delivery system, such as a controlled drug release system and faster dissolution rate.  

• The rheumatoid arthritis segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global indomethacin market is categorized into osteoarthritis, gout, ankylosing spondylitis, rheumatoid arthritis, and others. Among these, the rheumatoid arthritis segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The sector growth is attributed to the increasing cases of rheumatoid arthritis, indomethacin is highly effective in rheumatoid arthritis, rising cases of the inflammatory conditions, genetic predisposition, and dysregulation of the immune system.

• The hospital pharmacies segment held a significant share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe.

Based on the distribution channel, the global indomethacin market is categorized as retail pharmacies, hospital pharmacies, online pharmacies, and others. Among these, the hospital pharmacies segment held a significant share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe. The segment growth is attributed to the personalized medications and treatment to the patients, availability of the skilled pharmacist giving better health outcome to patients, counselling and dispensing of medications facilities, cost-effective medications, and availability of the wide range of indomethacin products.

Regional Segment Analysis of the Global Indomethacin Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global indomethacin market over the predicted timeframe.

North America is anticipated to hold the largest share of the global indomethacin market over the predicted timeframe. North America’s indomethacin market is growing as a result of the high rates of arthritis and other inflammatory diseases, the region’s robust healthcare system, substantial healthcare spending, the presence of large pharmaceutical firms, and continuous research efforts. The expanding population of older individuals, who are at a greater risk for inflammatory diseases, contributes to the growth of the market. Indomethacin is widely available and accessible across hospitals, clinics, and pharmacies ascribed to the established healthcare system. The increasing health consciousness and awareness of how to manage chronic inflammatory conditions are driving patients to look for effective treatments, which is advantageous for the market.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The market for indomethacin in the Asia Pacific region is growing as a result of increased spending on healthcare, enhanced infrastructure, and heightened awareness of effective treatments. The burgeoning middle-class demographic and chronic illnesses result in to the drive the need for indomethacin. Nations such as China, India, and Japan play a pivotal role in its contribution. By forming strategic partnerships with local healthcare providers, pharmaceutical companies can ensure that indomethacin is available to a larger patient population. The region's economic growth is promoting improved healthcare systems and access to medications, especially in rural areas. The availability of generic Indomethacin is being driven by policies designed to enhance healthcare access and awareness in both rural and urban regions, thereby indirectly escalating the market growth.

Competitive Analysis:

The report offers an appropriate analysis of the key organizations/companies involved within the global indomethacin market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Hikma Pharmaceuticals PLC
• Cipla Inc.
• Endo Pharmaceuticals Inc.
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company plc
• Amneal Pharmaceuticals LLC
• Lupin Limited
• Sandoz International GmbH
• Novartis AG
• Alkem Laboratories Ltd.
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Glenmarke Pharmaceuticals Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In December 2024, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, developed Indomethacin Suppositories (50mg) dose making it the second generic on the market. The product is indicated for moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis. This expansion broadens the choice of medicines available to doctors and patients in the US.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global indomethacin market based on the below-mentioned segments:

Global Indomethacin Market, By Dosage Form

• Suppositories
• Injections
• Capsules
• Suspension
• Others

Global Indomethacin Market, By Indications

• Osteoarthritis
• Gout
• Ankylosing Spondylitis
• Rheumatoid Arthritis
• Others

Global Indomethacin Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Others

Global Indomethacin Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa